ID   2F8 [Mouse hybridoma against human EGFR]
AC   CVCL_F1XQ
DR   ABCD; ABCD_AH809
RX   Patent=US7247301;
RX   PubMed=15383606;
CC   Biotechnology: The monoclonal antibody produced by this hybridoma is known as zalutumumab and was intended to be used for the treatment of head and neck cancers but was abandonned due to lack of benefits.
CC   Monoclonal antibody isotype: IgG1, kappa.
CC   Monoclonal antibody target: UniProtKB; P00533; Human EGFR (Note=Immunized with both A-431 cells (Cellosaurus=CVCL_0037) and purified EGFR).
CC   Miscellaneous: As the immunized splenic B-cells are from HuMAb mice the produced mAB is of human origin.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 27-11-25; Last updated: 27-11-25; Version: 1
//
RX   Patent=US7247301;
RA   van de Winkel, Jan G.J.
RA   van Dijk, Marcus Antonius
RA   Gerritsen, Arnout F.
RA   Halk, Edward L.
RT   "Human monoclonal antibodies to epidermal growth factor receptor (EGFR).";
RL   Patent number US7247301, 24-Jul-2007.
//
RX   PubMed=15383606; DOI=10.4049/jimmunol.173.7.4699;
RA   Bleeker, Wim K.
RA   Lammerts van Bueren, Jeroen J.
RA   van Ojik, Heidi H.
RA   Gerritsen, Arnout F.
RA   Pluyter, Marielle
RA   Houtkamp, Mischa Antonius
RA   Halk, Edward L.
RA   Goldstein, Joel
RA   Schuurman, Janine
RA   van Dijk, Marcus Antonius
RA   van de Winkel, Jan G.J.
RA   Parren, Paul W.H.I.
RT   "Dual mode of action of a human anti-epidermal growth factor receptor
RT   monoclonal antibody for cancer therapy.";
RL   J. Immunol. 173:4699-4707(2004).
//